Company intelligence / Profile preview
Bioxodes
Gosselies*, Belgiumbioxodes.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Bioxodes’ lead candidate, BIOX‑101 (Ir-CPI), demonstrated positive interim results in a Phase IIa trial for intracerebral hemorrhage. The drug showed safety and encouraging efficacy signals—reducing hematoma and edema volume with no increase in bleeding risk or serious adverse events. Enrollment was stopped early due to meeting endpoints, and the company plans to initiate a potentially registrational Phase IIb study in the first half of 2027[2].
- Therapeutic areas
- ImmunologyCardiovascularNeurology
- Modalities
- Peptide/protein therapeutics (derived from tick salivary proteins)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major pharmaceutical partnerships disclosed as of May 2025. Academic collaborations are noted below.
Beyond the preview
Go deeper on Bioxodes.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bioxodes.